China’s BGNE IPOs 7.59M* ADSs @$24.00: http://finance.yahoo.com/news/beigene-announces-pricing-initial-public-023037242.html BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics. With a team of 215+ scientists and staff, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. Each ADS is equivalent to 13 ordinary shares. *Assuming exercise of underwriter’s option.